ArticlesPrevalence of the Metabolic Syndrome in Veterans with SchizophreniaMEYER, JONATHAN MD; LOH, CATHERINE PhD; LECKBAND, SUSAN G. RPh, BCPP; BOYD, JENNIFER A. PharmD, BCPP; WIRSHING, WILLIAM C. MD; PIERRE, JOSEPH M. MD; WIRSHING, DONNA MD Author Information MEYER: Veterans Affairs San Diego Healthcare System and University of California, San Diego School of Medicine; LOH and LECKBAND: Veterans Affairs San Diego Healthcare System; BOYD: Greater Los Angeles Veterans Affairs Healthcare System; W. C. WIRSHING and PIERRE: University of California, Los Angeles School of Medicine; D. WIRSHING: Greater Los Angeles Veterans Affairs Healthcare System and University of California, Los Angeles School of Medicine. Please send correspondence and reprint requests to: Jonathan Meyer, MD, 3350 La Jolla Village Drive (116-A), San Diego, CA 92161. [email protected]. Supported by funding from the VA VISN 22 MIRECC and Pfizer, Inc. Presented at the American Psychiatric Association Annual Meeting, Atlanta, May 23, 2005. Journal of Psychiatric Practice: January 2006 - Volume 12 - Issue 1 - p 5-10 Buy Abstract The metabolic syndrome has become a focus of clinical attention due to its high prevalence in the United States (23%) and impact on cardiovascular risk, yet limited data exist on the prevalence of this syndrome among U.S. veterans with schizophrenia. Methods: A convenience sample of patients diagnosed with schizophrenia or schizoaffective disorder was obtained from inpatient units and outpatient clinics at Veterans Affairs medical centers in San Diego and Los Angeles. Results: In this predominantly male (92.5%) sample of 80 veterans, with mean age of 49.0 years, the age-adjusted prevalence of the metabolic syndrome was 51.2%, more than twice the age-adjusted prevalence in the general U.S. population. The female cohort was small (n = 6), but had a greater mean body mass index and higher prevalence of metabolic syndrome than the male subjects. Conclusions: The metabolic syndrome is highly prevalent in this sample of patients with schizophrenia and represents an enormous source of cardiovascular disease risk. Clinicians who treat patients with schizophrenia should monitor for the parameters that define the metabolic syndrome as part of the ongoing management of patients treated with antipsychotics. Copyright © 2006 Wolters Kluwer Health, Inc. All rights reserved.